Zobrazeno 1 - 5
of 5
pro vyhledávání: '"502"'
Autor:
Thomas A. Warr, Rachel Neuwirth, Robert M. Rifkin, Ian W. Flinn, Yousuf Gaffar, James A. Reeves, Veena Charu, James Essell, Yanyan Zhu, Ruben Niesvizky, Billy Clowney, Nashat Y. Gabrail, Dixie-Lee Esseltine, Liviu Niculescu, Jennifer Elliott
Publikováno v:
Journal of Clinical Oncology. 33:3921-3929
Purpose The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with myeloma. Patients and Methods Patients (N = 502) were randomly assigned 1:1:1 to 24
Autor:
Dong-Wook Kim, Irina Dyagil, Athena Countouriotis, Tim H. Brümmendorf, Hagop M. Kantarjian, Hemant Malhotra, Karin Gogat, Carlo Gambacorti-Passerini, Jorge E. Cortes, Christine Powell, Laimonas Griskevicius
Publikováno v:
Journal of Clinical Oncology. 30:3486-3492
Purpose Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid le
Autor:
Stan B. Kaye, A. S. T. Planting, David Allman, Melanie Mackean, Osterwalder B, Bruno Reigner, T Griffin, Chris Twelves, Jan H.M. Schellens, Jaap Verweij
Publikováno v:
Journal of Clinical Oncology, 16(9), 2977-2985. American Society of Clinical Oncology
PURPOSE Capecitabine is an orally administered fluoropyrimidine carbamate selectively activated to fluorouracil (5-FU) in tumors. It passes through the intestinal mucosal membrane intact and is subsequently activated by a cascade of three enzymes tha
Autor:
Daniel J. Schaid, Clive S. Grant, James N. Ingle, James E. Krook, Jerry A. Katzmann, Nick J. Gonchoroff, Lester E. Wold, Thomas E. Witzig, James B. Gerstner, John F. Barlow
Publikováno v:
Journal of Clinical Oncology. 11:351-359
PURPOSE AND METHODS To help clarify the clinical utility of flow-cytometric parameters, we performed flow cytometry on archival paraffin-embedded primary breast cancers from 502 patients treated on two adjuvant chemotherapy protocols performed by the
Publikováno v:
Journal of Clinical Oncology. 29:e14613-e14613
Almost all patients with advanced gastric cancer will eventually develop progressive disease after first-line chemotherapy. However, the role of subsequent salvage chemotherapy remains controversial. The purpose of this study was to evaluate prognost